C-terminal cross-linking telopeptide levels in COVID-19 patients: A prospective case-control study

ArticleAçık Erişim

Özet

Background. Coronavirus disease 19 (COVID-19) is a viral infection mediated by coronavirus-2 that causes severe acute respiratory syndrome (SARS-CoV-2). The disease may affect biochemical parameters and electrolytes. C-terminal cross-linking telopeptide (CTX-I) is released during mature bone resorption and is a biomarker for predicting bone resorption. Objectives. As the pandemic progressed, understanding the effects of COVID-19 disease remained critical. Inflammatory responses triggered by the virus can result in a bone metabolism regulation imbalance. As such, this study aimed to analyze serum levels of CTX-I, calcium (CA), phosphorus (P), magnesium (Mg), C-reactive protein (CRP), and alkaline phosphatase (ALP) in COVID-19 patients to investigate the relationship between bone resorption and the disease. Materials and methods. The study included 56 individuals with COVID-19 (divided into mild, moderate and severe subgroups depending on disease severity) and 25 healthy adults as a control group. Serum CTX-I concentrations were measured with enzyme-linked immunosorbent assay (ELISA). In addition, CRP, Ca, Mg, P, and ALP levels were measured using an automated clinical chemistry analyzer. Results. Serum CTX-I levels were significantly higher in COVID-19 patients than in the control group (p < 0.05). Furthermore, a positive weak relationship was detected between CRP and CTX-I (r = 0.303, p < 0.05). Conclusions. Increased serum CTX-I levels in the patient group caused COVID-19-driven bone degradation, though serum CTX-I levels did not differ according to disease severity. © 2024 Wroclaw University of Medicine. All rights reserved.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/11979Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.17219/acem/185254Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorGul, Mehmet Ali
dc.contributor.authorKurt, Nezahat
dc.contributor.authorOzgeris, Fatma Betul
dc.contributor.authorYuce, Neslihan
dc.contributor.authorKocak, Omer Faruk
dc.contributor.authorParlak, Emine
dc.date.accessioned2026-10-18T20:26:57.019754471Z
dc.date.available2026-10-18T20:26:57.019754471Z
dc.date.issued2024
dc.description.abstractBackground. Coronavirus disease 19 (COVID-19) is a viral infection mediated by coronavirus-2 that causes severe acute respiratory syndrome (SARS-CoV-2). The disease may affect biochemical parameters and electrolytes. C-terminal cross-linking telopeptide (CTX-I) is released during mature bone resorption and is a biomarker for predicting bone resorption. Objectives. As the pandemic progressed, understanding the effects of COVID-19 disease remained critical. Inflammatory responses triggered by the virus can result in a bone metabolism regulation imbalance. As such, this study aimed to analyze serum levels of CTX-I, calcium (CA), phosphorus (P), magnesium (Mg), C-reactive protein (CRP), and alkaline phosphatase (ALP) in COVID-19 patients to investigate the relationship between bone resorption and the disease. Materials and methods. The study included 56 individuals with COVID-19 (divided into mild, moderate and severe subgroups depending on disease severity) and 25 healthy adults as a control group. Serum CTX-I concentrations were measured with enzyme-linked immunosorbent assay (ELISA). In addition, CRP, Ca, Mg, P, and ALP levels were measured using an automated clinical chemistry analyzer. Results. Serum CTX-I levels were significantly higher in COVID-19 patients than in the control group (p < 0.05). Furthermore, a positive weak relationship was detected between CRP and CTX-I (r = 0.303, p < 0.05). Conclusions. Increased serum CTX-I levels in the patient group caused COVID-19-driven bone degradation, though serum CTX-I levels did not differ according to disease severity. © 2024 Wroclaw University of Medicine. All rights reserved.
dc.identifier.doi10.17219/acem/185254
dc.identifier.eissn2451-2680
dc.identifier.endpage698
dc.identifier.issn1899-5276
dc.identifier.issue7
dc.identifier.pmid38515258
dc.identifier.scopus2-s2.0-85200169315
dc.identifier.startpage691
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/11979
dc.identifier.volume33
dc.identifier.wosWOS:001189427300001
dc.language.isoen
dc.publisherWroclaw University of Medicine
dc.relation.ispartofAdvances in Clinical and Experimental Medicine
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectbone
dc.subjectCOVID-19
dc.subjectCTX-I
dc.subjectAdult
dc.subjectAged
dc.subjectAlkaline Phosphatase
dc.subjectBiomarkers
dc.subjectBone Resorption
dc.subjectC-Reactive Protein
dc.subjectCalcium
dc.subjectCase-Control Studies
dc.subjectCollagen Type I
dc.subjectFemale
dc.subjectHumans
dc.subjectMagnesium
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectPeptides
dc.subjectPhosphorus
dc.subjectProspective Studies
dc.subjectSARS-CoV-2
dc.subjectSeverity of Illness Index
dc.subjectC reactive protein
dc.subjectc terminal crosslinking telopeptide i
dc.subjectcarboxy terminal telopeptide
dc.subjectunclassified drug
dc.subjectbiological marker
dc.subjectcollagen type 1
dc.subjectcollagen type I trimeric cross-linked peptide
dc.subjectpeptide
dc.titleC-terminal cross-linking telopeptide levels in COVID-19 patients: A prospective case-control study
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus0
rdl.citation.wos0
rdl.departmentDepartment of Medical Biochemistry, Faculty of Medicine, Erzincan Binali Yildirim University, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)